| Clinical
Trial: |
S0211
–Stage III and IV Ovarian Cancer |
| Governing Group: |
Southwest Oncology
Group |
| Title: |
“A Phase
II Trial of STI571 (Gleevec) for the Treatment of Platinum and Tazane
Refractory Stage III and IV Epithelial Ovarian Cancer and Primary
Peritoneal Cancer.” |
Eligibility:
- Histologically or pathologically confirmed epithelial carcinoma
of the ovary or primary peritoneal serous papillary carcinoma.
- Stage III or IV epithelial ovarian cancer.
- Patients must not have mixed Mullerian Tumors or borderline
ovarian tumors.
- Immunohistochemical tumor expression of KIT and/or PDGFR.
- Patients must have relapsed (or had a best response of increasing
disease) within six (6) months of frontline chemotherapy with
platinum and taxane.
- Patients must have measurable disease.
- Besides the frontline platinum/taxane chemotherapy one additional
prior chemotherapy regimen allowed.
- Prior hormonal and/or biologic therapy allowed.
- Prior radiation allowed (no more than 25% of bone marrow encompassed).
- Performance Status 0-1.
- Adequate liver and renal function.
- WBC within normal limits.
- Specimens available for pathology review and correlative studies.
- Patients must not have class ¾ cardiac problems.
- Patients must not be pregnant or nursing.
- Patients must not be taking therapeutic dose of coumadin.
- Some prior malignancies are allowed (eg. Basal cell, squamous
cell, in situ cervical).
|
| Clinical
Trial: |
182
- Ovarian Cancer |
| Governing Group: |
Gynecological
Oncology Group |
| Title: |
"A Phase III
Randomized Trial of Paclitaxel and Carboplatin Versus Triplet or Sequential
Doublet Combination in Patients with Epithelial Ovarian or Primary
Peritoneal Carcinoma." |
Eligibility:
- Patients with a histologic diagnosis of primary peritoneal
carcinoma or epithelial ovarian carcinoma, Stage III or IV, with
either optimal (less than 1 cm residual disease) or suboptimal
residual disease following initial surgery.
- All patients must have had appropriate surgery for ovarian
or peritoneal carcinoma with appropriate tissue available for
histologic evaluation to confirm diagnosis and stage.
- Patients with the following hisologic epithelial cell types
are eligible: serous adenocarcinoma, endometrioid adenocarcinoma,
mucinous adenocarcinoma, undifferentiated carcinoma, clear cell
adenocarcinoma, mixed epithelial carcinoma, transitional cell
carcinoma, malignant Brenner's Tumor, or adenocarcinoma N.O.S.
- Patients with borderline carcinomas are not eligible along
with germ cell, sex cord-stromal tumors, carcinosarcomas, mixed
mullerian, metastatic carcinomas from other sites to the ovary.
- No previous radiation to any portion of the abdominal cavity
or pelvis.
|
